1. |
BATEMAN E D, HURD S S, BARNES P J, et al. Global Strategy for asthma management and prevention: GINA executive Summary [J].Eur Respir J,2008,(1):143-178..
|
2. |
ADAMS N P, JONES P W. The doseresponse characteristics of inhaled corticosteroids when used to treat asthma: an overview of Cochrane systematic reviews[J]. Respir Med,2006,100(8):1297-306..
|
3. |
National Asthma Education and Prevention Program. Expert Panel Report 3(EPR3): Guidelines for the Diagnosis and Management of AsthmaSummary Report 2007[J]. Allergy Clin Immunol,2007,120(5 Suppl):S94-138..
|
4. |
DYER M J, HALPIN D M, STEIN K. Inhale ciclesonide versus inhales budesonide or inhaled beclomethasone or inhaled fluticasone for chronic asthma in adults: a systematic review[J]. BMC Fam Pract,2006,7:34..
|
5. |
KRISHNA SWAMI S, HOCHOUSE G, MLILMANN H, et al. Interpretation of absorption rate data for inhaled fluticasone propionate obtained in compartmental pharma cokinetic modeling[J]. Int J Clint Pharmacol Ther,2005,43(3):117-122..
|
6. |
HAAHTELA T, TUOMISTO L E, PIETINALHO A, et al. A 10 year asthmaprogramme in Finland:major change for the better[J]. Thorax,2006,61(8):663-670..
|
7. |
RABE K F, HURD S, ANZUETO A, et al. Global strategy for the diagnosis,management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary[J]. Am J Respir Crit Care Med,2007,176(6):532-555..
|
8. |
LIPWORTH B J, KALINER M A, LAFORCE C F, et al. Effect of ciclesonide and fluticasone on hypothalamicpituitaryadrenal axis function in adults with mildtomoderate persistent asthma[J]. Ann Allergy Asthma Immunol,2005,94(4):465-472..
|
9. |
KELLY H W. Pharmaceutical characterist ICSs that influence the clinical efficacy of inhaled corticosteroids[J]. Ann Allergy Asthma Immunol,2003,91(4):326-333.
|
10. |
崔姝梅,徐作军.189例支气管哮喘病人吸入糖皮质激素使用方法的状况调查[J].中华结核和呼吸杂志,2004,27:418-419..
|
11. |
林丽君.哮喘的糖皮质激素吸入疗法[J].现代医药卫生,2004,20(4):250-251..
|
12. |
王志虹,林江涛.定量气雾吸入剂的正确使用[J].中华全科医师杂志,2003,2:17..
|